Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004,...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of WVE is 21 and suggests 149% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
